GO:0070102 interleukin-6-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070102 describes the molecular signal cascade triggered when interleukin-6 (IL-6) binds its surface receptor, culminating in regulation of downstream cellular processes such as transcription.
• The canonical IL-6 signaling axis proceeds through JAK2-mediated phosphorylation of STAT3, which then translocates to the nucleus to control target gene expression.
• IL-6 signaling is not confined to immune cells; it operates in trabecular meshwork cells, adrenal chromaffin cells, hepatocytes, cholangiocytes, and multiple tumor types.
• Dysregulated IL-6-mediated signaling contributes to cancer progression, kidney ischemia/reperfusion injury, hepatic acute phase response, and disorganized angiogenesis.
• IL-6 trans-signaling can antagonize TGF-β signaling, revealing extensive crosstalk between cytokine pathways.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are essential to dissect causal roles of individual nodes in this pathway.
Description
The interleukin-6-mediated signaling pathway (GO:0070102) is the series of molecular events initiated when interleukin-6 (IL-6) binds to its receptor on the surface of a target cell, ending with regulation of a downstream cellular process such as transcription. IL-6 is a pleiotropic cytokine, and this GO term captures the entire signal transduction cascade rather than a single molecular function. The pathway is activated in diverse physiological contexts, including immune regulation, acute phase response, neuroendocrine differentiation, and tissue repair. Because it operates in many cell types, the pathway is a central node in both normal physiology and disease. In trabecular meshwork cells, IL-6-mediated trans-signaling inhibits transforming growth factor-β signaling, demonstrating pathway crosstalk. In oral squamous cell carcinoma, IL-6-mediated inflammasome activation promotes tumor progression through a JAK2/STAT3/Sox4/NLRP3 axis. In kidney ischemia/reperfusion injury, meprin β expression modulates the IL-6-mediated JAK2-STAT3 signaling pathway. These examples illustrate why GO:0070102 is a high-priority annotation for researchers studying inflammation, cancer, and tissue injury. Understanding the pathway at the level of individual genes and post-translational events enables precise experimental design, including CRISPR knockout and knock-in studies.
interleukin-6-mediated signaling pathway At A Glance
| GO ID | GO:0070102 |
|---|---|
| GO term | interleukin-6-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | IL-6-mediated signaling pathway; interleukin-6-mediated signalling pathway |
| Definition | The series of molecular signals initiated by interleukin-6 binding to a receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| Major function | Transduces extracellular IL-6 signals into changes in gene expression and cellular behavior, often via JAK2-STAT3. |
| Key transducer | JAK2 and STAT3 are recurrent nodes in this pathway. |
| Crosstalk | IL-6 trans-signaling can inhibit TGF-β signaling in trabecular meshwork cells. |
| Disease relevance | Implicated in cancer progression, kidney injury, hepatic acute phase response, and angiogenesis. |
What Is GO:0070102?
GO:0070102, interleukin-6-mediated signaling pathway, is defined as the series of molecular signals initiated by interleukin-6 binding to a receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. In other words, it is the full relay from ligand-receptor engagement through intracellular transducer activation to a functional cellular outcome. The term is a biological_process in the Gene Ontology and includes both classical signaling through membrane-bound IL-6 receptor and trans-signaling mechanisms where soluble receptor complexes participate. Synonyms include IL-6-mediated signaling pathway and interleukin-6-mediated signalling pathway.
Why Is interleukin-6-mediated signaling pathway Important in Cell Biology?
GO:0070102 is important because IL-6-mediated signaling is a central communication hub that converts extracellular cytokine cues into transcriptional programs controlling inflammation, proliferation, differentiation, and survival. Its dysregulation is linked to cancer progression, kidney ischemia/reperfusion injury, hepatic acute phase response, and disorganized angiogenesis. Because the pathway operates in many cell types, including adrenal chromaffin cells, trabecular meshwork cells, and cholangiocytes, it is a recurring annotation in studies of neuroendocrine function, ocular physiology, and liver biology. Researchers use this GO term to systematically annotate genes and to design experiments that test causality, such as CRISPR knockout of JAK2 or STAT3.
• Provides a standardized annotation for any gene product participating in IL-6 signal relay from receptor to transcription.
• Central to cancer biology, where IL-6-mediated JAK2/STAT3/Sox4/NLRP3 signaling promotes oral squamous cell carcinoma progression.
• Modulates kidney ischemia/reperfusion injury through meprin β-dependent effects on JAK2-STAT3 signaling.
• Controls hepatic acute phase response, with RORα acting as a suppressor of IL-6-mediated hepatic acute phase response.
• Regulates angiogenesis; IL-6-mediated epigenetic control of VEGFR2 induces disorganized angiogenesis in breast tumors.
• Influences neuroendocrine differentiation in prostate cancer cells via PI3K activation.
• Participates in crosstalk with TGF-β signaling, as IL-6 trans-signaling inhibits TGF-β signaling in trabecular meshwork cells.
• Is active in adrenal medullary chromaffin cells, linking immune signaling to neuroendocrine tissue.
• Drives cholangiocyte spheroid proliferation via TGF-β1-triggered IL-6-mediated STAT3 signaling.
• Serves as a template for CRISPR functional genomics, including knockout, point mutation, and knock-in models.
What Happens During interleukin-6-mediated signaling pathway?
Ligand binding and receptor engagement
In simple terms: IL-6 docks onto its receptor on the cell surface, starting the signal.
The pathway begins when interleukin-6 binds to a receptor on the surface of a target cell, as specified in the GO definition. This engagement can occur through membrane-bound receptor or through trans-signaling complexes, and in trabecular meshwork cells IL-6-mediated trans-signaling has been shown to inhibit TGF-β signaling. The receptor engagement step is the initiating event that defines membership in GO:0070102.
JAK2 activation and STAT3 phosphorylation
In simple terms: Inside the cell, JAK2 tags STAT3 with phosphate groups, turning STAT3 into a signal carrier.
A recurrent intracellular event in this pathway is activation of JAK2 and subsequent phosphorylation of STAT3. In oral squamous cell carcinoma, IL-6-mediated inflammasome activation proceeds via a JAK2/STAT3/Sox4/NLRP3 signaling pathway. In kidney ischemia/reperfusion injury, meprin β expression modulates the IL-6-mediated JAK2-STAT3 signaling pathway. In cholangiocyte spheroids, TGF-β1 triggers proliferation via IL-6-mediated STAT3 signaling. These studies establish JAK2-STAT3 as a core transducer module within GO:0070102.
STAT3 nuclear translocation and transcriptional regulation
In simple terms: The activated signal carrier moves into the nucleus and switches genes on or off.
The GO definition explicitly ends with regulation of a downstream cellular process, e.g. transcription. Consistent with this, IL-6-mediated signaling controls gene expression programs such as the hepatic acute phase response, where RORα suppresses the IL-6-mediated hepatic acute phase response. IL-6-mediated epigenetic control of the VEGFR2 gene induces disorganized angiogenesis in human breast tumors, illustrating transcriptional and epigenetic outputs of the pathway.
Crosstalk with TGF-β and PI3K branches
In simple terms: The IL-6 signal can talk to other signaling systems, changing the final outcome.
IL-6-mediated signaling is not isolated; it intersects with other pathways. IL-6-mediated trans-signaling inhibits transforming growth factor-β signaling in trabecular meshwork cells. In prostate cancer LNCaP cells, androgen signaling regulates IL-6-mediated PI3K activation and neuroendocrine differentiation. These branch points expand the functional scope of GO:0070102 beyond a single linear cascade.
Cell-type-specific outcomes
In simple terms: The same pathway can do different jobs depending on the cell type.
The outcome of IL-6-mediated signaling varies by cellular context. In adrenal medullary chromaffin cells, IL-6-mediated signaling has been characterized as a functional pathway. In cholangiocyte spheroids, it drives proliferation. In breast tumor angiogenesis, it induces disorganized vessel formation. This context dependence is a key reason the GO term is defined broadly as ending with regulation of a downstream cellular process.
Key Genes Involved in GO:0070102 interleukin-6-mediated signaling pathway
The following genes and proteins are recurrently implicated in interleukin-6-mediated signaling pathway (GO:0070102) across the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL6 | Extracellular ligand that initiates the pathway | Pathway-initiating cytokine; target for knockout and overexpression studies |
| IL6R | Surface receptor for IL-6 | Receptor engagement step; relevant to trans-signaling studies |
| JAK2 | Kinase that phosphorylates STAT3 | Core transducer; modulated by meprin β in kidney injury |
| STAT3 | Transcription factor activated downstream of JAK2 | Central node in cancer and cholangiocyte proliferation |
| Sox4 | Transcription factor in the JAK2/STAT3/Sox4/NLRP3 axis | Promotes oral squamous cell carcinoma progression |
| NLRP3 | Inflammasome component downstream of IL-6 signaling | Links IL-6 signaling to inflammasome activation in cancer |
| Meprin β | Modulates JAK2-STAT3 signaling | Modifies kidney ischemia/reperfusion injury response |
| TGF-β | Crosstalk partner inhibited by IL-6 trans-signaling | Relevant to trabecular meshwork biology |
| RORα | Suppressor of IL-6-mediated hepatic acute phase response | Negative regulator in liver acute phase response |
| VEGFR2 | Angiogenesis receptor under IL-6-mediated epigenetic control | Induces disorganized angiogenesis in breast tumors |
| PI3K | Lipid kinase branch activated by IL-6 signaling | Linked to neuroendocrine differentiation in prostate cancer |
| Androgen receptor | Regulates IL-6-mediated PI3K activation | Context-dependent modulator in LNCaP cells |
| IL-6 receptor complex | Surface complex that binds IL-6 | Initiating component of GO:0070102 |
| STAT3 target genes | Downstream transcriptional outputs | Mediate acute phase response and proliferation |
| SOCS proteins | Canonical negative regulators of cytokine signaling | Generic pathway regulation; not directly cited in the verified list |
| gp130 | Shared signal-transducing subunit for IL-6 family cytokines | Generic pathway component; not directly cited in the verified list |
How Is interleukin-6-mediated signaling pathway Regulated?
Regulation of interleukin-6-mediated signaling pathway occurs at multiple levels. RORα suppresses the IL-6-mediated hepatic acute phase response, providing an example of negative regulation at the transcriptional output stage. Meprin β expression modulates the IL-6-mediated JAK2-STAT3 signaling pathway in ischemia/reperfusion-induced kidney injury, indicating that extracellular or membrane-associated proteases can tune pathway strength. IL-6-mediated trans-signaling inhibits TGF-β signaling in trabecular meshwork cells, showing that pathway activity can be redirected through crosstalk. Androgen signaling regulates IL-6-mediated PI3K activation and neuroendocrine differentiation in prostate cancer LNCaP cells, demonstrating hormonal control of a specific branch. These examples illustrate that GO:0070102 is not a fixed linear cascade but a regulated network responsive to cell-type-specific modulators.
interleukin-6-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| JAK2/STAT3/Sox4/NLRP3 | Oral squamous cell carcinoma progression | Knockout of STAT3 or Sox4 in OSCC cell lines |
| Meprin β | Kidney ischemia/reperfusion injury | Meprin β knockout or overexpression in renal epithelial cells |
| RORα | Hepatic acute phase response | RORα knockout hepatocytes with IL-6 stimulation |
| VEGFR2 | Disorganized angiogenesis in breast tumors | Epigenetic editing or knockout of VEGFR2 regulatory elements |
| PI3K / androgen receptor | Prostate cancer neuroendocrine differentiation | Androgen receptor point mutation or knockout in LNCaP cells |
Cancer progression and inflammasome activation
IL-6-mediated inflammasome activation promotes oral squamous cell carcinoma progression via the JAK2/STAT3/Sox4/NLRP3 signaling pathway. In breast tumors, IL-6-mediated epigenetic control of the VEGFR2 gene induces disorganized angiogenesis, linking the pathway to tumor vascularization. In prostate cancer LNCaP cells, androgen signaling regulates IL-6-mediated PI3K activation and neuroendocrine differentiation, connecting the pathway to tumor cell phenotype switching.
Kidney ischemia/reperfusion injury
Meprin β expression modulates the IL-6-mediated JAK2-STAT3 signaling pathway in ischemia/reperfusion-induced kidney injury, indicating that this pathway contributes to renal injury responses and is subject to modulation by meprin β.
Hepatic acute phase response
RORα suppresses the IL-6-mediated hepatic acute phase response, demonstrating that the pathway is a key driver of liver acute phase protein expression and that nuclear receptors can dampen this response.
Ocular and cholangiocyte biology
In trabecular meshwork cells, IL-6-mediated trans-signaling inhibits TGF-β signaling, which is relevant to ocular outflow physiology. In cholangiocyte spheroids, TGF-β1 triggers proliferation via IL-6-mediated STAT3 signaling, linking the pathway to biliary epithelial growth responses.
From interleukin-6-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does JAK2 mediate IL-6-driven STAT3 activation? | JAK2 knockout cell line |
| Does a specific STAT3 phosphorylation site control target gene expression? | STAT3 point-mutation knock-in |
| Can a disease-associated variant alter IL-6 pathway output? | Knock-in of the variant allele |
| Where does STAT3 localize after IL-6 stimulation? | Tagged knock-in of STAT3 |
| Does overexpression of meprin β enhance JAK2-STAT3 signaling? | Meprin β overexpression model |
| Does RORα suppress acute phase genes? | RORα overexpression or knockout hepatocytes |
How to Study the interleukin-6-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptional changes | Identify IL-6-responsive gene programs |
| Phospho-Western blot | JAK2 and STAT3 phosphorylation | Monitor pathway activation |
| qPCR | Expression of acute phase or target genes | Validate transcriptional outputs |
| Inflammasome assay | NLRP3 activation | Study cancer progression mechanisms |
| Angiogenesis assay | Vessel formation | Assess VEGFR2-driven disorganized angiogenesis |
| CRISPR knockout | Loss-of-function phenotype | Test causal role of JAK2, STAT3, Sox4 |
| CRISPR knock-in | Variant or tag effects | Model disease variants or track protein |
| Overexpression | Gain-of-function phenotype | Test meprin β or RORα effects |
Transcriptional readouts of pathway activation
Because GO:0070102 ends with regulation of transcription, RNA-seq and targeted qPCR of IL-6-responsive genes are standard methods. Studies of the hepatic acute phase response and VEGFR2 epigenetic control exemplify transcriptional and epigenetic readouts.
Phospho-protein analysis of JAK2-STAT3
Western blotting for phosphorylated JAK2 and STAT3 is widely used to monitor pathway activation, as shown in studies of meprin β modulation in kidney injury and TGF-β1-triggered STAT3 signaling in cholangiocyte spheroids.
Inflammasome and angiogenesis assays
NLRP3 inflammasome activation and angiogenesis assays can measure downstream phenotypes of IL-6 signaling, as demonstrated in oral squamous cell carcinoma and breast tumor angiogenesis studies.
CRISPR functional genomics
CRISPR knockout, point mutation, and knock-in approaches are used to test causality of individual pathway nodes, including JAK2, STAT3, Sox4, and NLRP3.
How CRISPR Can Be Used to Study GO:0070102 interleukin-6-mediated signaling pathway
Knockout
CRISPR knockout of JAK2, STAT3, Sox4, or NLRP3 can determine whether these genes are required for IL-6-mediated signaling outputs such as inflammasome activation or proliferation.
Point Mutation
Point mutation of STAT3 phosphorylation sites or of disease-associated variants can reveal which residues are essential for downstream transcription and phenotype.
Knock-in
Knock-in of tagged STAT3 or of disease-relevant alleles enables tracking of protein localization and modeling of variant effects within the pathway.
Overexpression
Overexpression of meprin β or RORα can test gain-of-function effects on JAK2-STAT3 signaling and acute phase response suppression.
How EDITGENE Supports interleukin-6-mediated signaling pathway Research
Researchers studying interleukin-6-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway output, whether a specific residue is required for signal transduction, or whether a disease variant alters transcriptional responses. EDITGENE provides the CRISPR tools and cell models to answer these questions with rigor.
Contact EDITGENE today to design your custom CRISPR model for interleukin-6-mediated signaling pathway research.
Frequently Asked Questions About interleukin-6-mediated signaling pathway
What is GO:0070102?
GO:0070102 is the Gene Ontology term for interleukin-6-mediated signaling pathway, defined as the series of molecular signals initiated by interleukin-6 binding to a receptor on the surface of a target cell, and ending with regulation of a downstream cellular process, e.g. transcription.
What genes are involved in interleukin-6-mediated signaling pathway?
Key genes include IL6, IL6R, JAK2, STAT3, Sox4, NLRP3, meprin β, RORα, VEGFR2, and PI3K, as reported in studies of cancer, kidney injury, liver acute phase response, and angiogenesis.
How does IL-6 activate STAT3?
IL-6 binding to its receptor activates JAK2, which phosphorylates STAT3; phosphorylated STAT3 then regulates transcription of target genes.
What diseases are linked to IL-6-mediated signaling?
The pathway is linked to oral squamous cell carcinoma progression, kidney ischemia/reperfusion injury, hepatic acute phase response, breast tumor angiogenesis, and prostate cancer neuroendocrine differentiation.
What is IL-6 trans-signaling?
IL-6 trans-signaling involves soluble receptor complexes and can inhibit TGF-β signaling, as shown in trabecular meshwork cells.
How can CRISPR be used to study GO:0070102?
CRISPR knockout, point mutation, knock-in, and overexpression can test the causal role of JAK2, STAT3, Sox4, NLRP3, meprin β, and RORα in pathway output.
What cell types show IL-6-mediated signaling?
The pathway has been studied in trabecular meshwork cells, adrenal medullary chromaffin cells, oral squamous cell carcinoma cells, kidney cells, hepatocytes, cholangiocyte spheroids, breast tumor cells, and prostate cancer LNCaP cells.
Does IL-6 signaling crosstalk with TGF-β?
Yes, IL-6-mediated trans-signaling inhibits TGF-β signaling in trabecular meshwork cells.
What is the role of RORα in IL-6 signaling?
RORα suppresses the IL-6-mediated hepatic acute phase response.
How is IL-6-mediated signaling measured in the lab?
Common methods include phospho-Western blot for JAK2-STAT3, RNA-seq or qPCR for transcriptional outputs, inflammasome assays, angiogenesis assays, and CRISPR functional genomics.
Conclusion
GO:0070102, interleukin-6-mediated signaling pathway, is a broadly relevant biological process that converts extracellular IL-6 cues into transcriptional and phenotypic changes through JAK2-STAT3 and intersecting branches such as PI3K and TGF-β crosstalk. Its involvement in cancer, kidney injury, liver acute phase response, and angiogenesis makes it a high-value target for functional genomics. CRISPR-based knockout, point mutation, knock-in, and overexpression models provide the causal evidence needed to move from correlation to mechanism. Researchers can leverage these approaches to dissect pathway nodes and identify new therapeutic opportunities.
References
- 1. Inoue-Mochita M et al.. 2018. Interleukin-6-mediated trans-signaling inhibits transforming growth factor-β signaling in trabecular meshwork cells.. J Biol Chem 293(28):10975-10984 PMID: 29752408
- 2. Xiao L et al.. 2022. Interleukin-6 mediated inflammasome activation promotes oral squamous cell carcinoma progression via JAK2/STAT3/Sox4/NLRP3 signaling pathway.. J Exp Clin Cancer Res 41(1):166 PMID: 35513871
- 3. Abousaad S et al.. 2022. Meprin β expression modulates the interleukin-6 mediated JAK2-STAT3 signaling pathway in ischemia/reperfusion-induced kidney injury.. Physiol Rep 10(18):e15468 PMID: 36117389
- 4. Jenkins DE et al.. 2016. Interleukin-6-mediated signaling in adrenal medullary chromaffin cells.. J Neurochem 139(6):1138-1150 PMID: 27770433
- 5. Yi J et al.. 2025. Transforming growth factor-β1 triggers the proliferation of human cholangiocyte spheroids via interleukin-6-mediated STAT3 signaling.. Mol Biol Rep 53(1):168 PMID: 41351799
- 6. Kim JY et al.. 2019. RORα suppresses interleukin-6-mediated hepatic acute phase response.. Sci Rep 9(1):11798 PMID: 31409825
- 7. Hegde M et al.. 2020. Interleukin-6-mediated epigenetic control of the VEGFR2 gene induces disorganized angiogenesis in human breast tumors.. J Biol Chem 295(34):12086-12098 PMID: 32636303
- 8. Xie S et al.. 2004. Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells.. Prostate 60(1):61-7 PMID: 15129430
